Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists (Q44387572)

2 December 2017

Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists (English)

1 reference

2 December 2017

5

1 reference

2 December 2017

Glenn Hunt

4

0 references

Gin Malhi

6

object named as

Gin Malhi

1 reference

2 December 2017

Garry Walter

1

1 reference

2 December 2017

Amy DeLaroche

2

1 reference

2 December 2017

Nerissa Soh

3

1 reference

2 December 2017

Tim Lambert

7

1 reference

2 December 2017

Christoph Correll

8

1 reference

2 December 2017

Joseph Rey

9

1 reference

2 December 2017

1 August 2008

1 reference

2 December 2017

Australasian Psychiatry

1 reference

2 December 2017

16

1 reference

2 December 2017

4

1 reference

2 December 2017

253-262

1 reference

New users of antipsychotic medications among children enrolled in TennCare

2 December 2017

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Trends in antipsychotic use in a Texas medicaid population of children and adolescents: 1996 to 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Prescribing of psychotropic medications for children by Australian pediatricians and child psychiatrists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Second-generation antipsychotic medications in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Review of antipsychotics in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Metabolic side effects of atypical antipsychotics in children: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Update and recommendations for the use of antipsychotics in early-onset psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Antipsychotic medications for children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Children with schizophrenia: clinical picture and pharmacological treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Tolerability profile of atypical antipsychotics in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

A comparison of risperidone-induced weight gain across the age span

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Childhood obesity: public-health crisis, common sense cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Olanzapine versus placebo in the treatment of adolescents with bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Risperidone-associated diabetes mellitus: a pharmacovigilance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Risperidone-associated diabetes mellitus in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Antipsychotics and the risk of diabetes: a general data review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

The effect of atypical antipsychotic agents on prolactin levels in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

The Effect of Long-Term Antipsychotic Treatment on Prolactin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Effects of short- and long-term risperidone treatment on prolactin levels in children with autism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Female puberty: clinical implications for the use of prolactin-modulating psychotropics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Elevated prolactin in pediatric patients on typical and atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Growth and sexual maturation during long-term treatment with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Retrospective Study of Hepatic Enzyme Elevations in Children Treated With Olanzapine, Divalproex, and Their Combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

"Real world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Clinicians' recognition of the metabolic adverse effects of antipsychotic medications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patients aged under 18 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

Trends in the Use of Typical and Atypical Antipsychotics in Children and Adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10398560801958549

10.1080/10398560801958549

21 January 2018

Identifiers

DOI

1 reference

2 December 2017

1 reference